Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
And to add to the above....another American was recently appointed to the board:
" He has been a member of the national Board of Directors of the American Cancer Society since 2019"
Mark A. Goldberg, MD
Non Executive Director
Mark A. Goldberg, MD, is a medical oncologist and hematologist and a biotechnology executive. In addition to being a Non-executive Director of Avacta, he currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Blueprint Medicines, and Walden Biosciences. Dr. Goldberg was part of the executive management team of Synageva Biopharma from 2011 until 2014. Prior to that, he served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 until 2011, including as senior vice president of Clinical Development. Prior to joining Genzyme, Dr. Goldberg was a full-time staff physician at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where he still holds an appointment. He is an associate professor of Medicine (part-time) at Harvard Medical School. Dr. Goldberg is also a longtime American Cancer Society (ACS) and ACS Cancer Action Network volunteer. Dr. Goldberg was a member of the American Cancer Society New England Division Board from 2010-2017. He has been a member of the national Board of Directors of the American Cancer Society since 2019. He received his AB from Harvard College (magna cum laude) and his MD (cum laude) from Harvard Medical School (Harvard MIT Program in Health Sciences and Technology).
gmcc...thanks for the clarification.
However, it confirms...."The Company benefits from near-term revenues generated from Affimer diagnostics"
I'll be ****ed off if Institutional Investors are getting the numbers but we plebs aren't.
Thanks DJW:
In summary, the new anti SARS-CoV-2 S1 Affimer® technology has shown to improve the performance at lower viral loads by 2-3 Ct values compared with the 3 other antigen-based LFDs showing fitness for routine use to reduce infections when used in moderate-to-high intensity settings where high volumes of specimens are tested every day.
In this context, the questions raised by some national health authorities about the reliability of these tests, would be answered up to a certain extent by the new AffiDX® SARS-CoV-2 Antigen LFD as it has shown to require a lower viral count (confirmed by RTqPCR) to show positive within the cohort tested.
Cellar boy
@boy_cellar
·
1h
Just an FYI, #avct has commercial rights to its Pre|cision platform.
Avacta doesn't have a profit sharing agreement or royalties.
For any drug submitted to clinical trial, Bach biosciences can exercise their share options.
Our success is their success
https://twitter.com/boy_cellar/status/1485552721881092104
The invite to the road show states:
"The company benefits from near-term revenue generated from Affimer diagnostics"
Hopefully more will be revealed this week in the Trading Update.
https://twitter.com/boy_cellar/status/1484809079180693505/photo/1
Neutronic.....you've made a few fair points but it's a bigger story. A pal works in one of the UK's very big film studios and he's regularly tested with Chinese crap. Film production is a massive industry in this country, with money coming out of its ears....it doesn't need hand-outs. A big market. And that is just one example. Armed Forces? The news from Japan isn't so hot.
And what about Abingdon with its pending Avacta order. And Wetherby itself....30 or 40 highly skilled people working mainly on Affimer diagnostics. I think this is very early days for AffiDX.
Agent Provocateur:
"The continued high performance of the Affimer® reagent in the AffiDX® antigen test, despite the large number of mutations in the Omicron variant, is testament to the robustness of our platform technology.
Alastair Smith, Chief Executive of Avacta Group, commented:
"We believe COVID-19 testing remains a long-term commercial opportunity. We will therefore use the robustness of the Affimer(R) platform, and what we have learned about the SARS-CoV-2 virus, to generate the next generation antigen test that will be as resilient as possible to any future mutations.
"The performance of other marketed SARS-CoV-2 antigen lateral flow tests may well be adversely affected by the Omicron variant."
Building a plant to launch AVA6000 isn't the way the pharma industry works.....apparently. One of the hurdles a new product must endure is a large scale trial using a commercial ready plant. An eye-wateringingly expensive task which limits access to only the very biggest companies. The chances of Avacta raising enough cash to do this must be very limited....not to mention the time taken to build a plant. A licensing deal for their first product is much more likely.
Reaper.....exactly. Investors are not looking at the whole picture. Which includes dozens of people in Wetherby working on the future of LFD's. Not to mention entire companies such as Abingdon that only produce to AVCT's designs. And the likes of Medusa's investment. Someone wrote we might get two weeks sales in March.... P-L-E-A-S-E.....don't.